From: Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients
Platelet count (×103 cell/mm3) |
All patients mean ± SD, mean PLT, % drop to baseline |
Group 1 Triple (n 56), mean PLT, % drop to baseline |
Group 2 SOF/RBV (n 55) mean PLT, % drop to baseline |
Group 3 SIM/SOF (n 57) mean PLT, % drop to baseline | p value (among three groups) |
---|---|---|---|---|---|
Baseline PLT | 108.85 ± 39.74 | 136.89 ± 31.70 | 77.18 ± 18.01 | 111.84 ± 40.35 | < 0.001 |
Week 1 |
89.72 ± 27.93 18% |
86.89 ± 23.62 37% |
75.89 ± 14.09 3% |
105.84 ± 33.56 6% | < 0.001 |
Week 2 |
90.87 ± 33.90 17% |
99.50 ± 36.89 28% |
72.58 ± 12.30 7% |
100.04 ± 38.18 10% | < 0.001 |
Week 3 |
87.65 ± 25.17 20% |
96.05 ± 28.4 30% |
76.07 ± 13.23 2% |
90.58 ± 26.68 19% | < 0.001 |
Week 4 |
88.46 ± 32.08 19% |
101.71 ± 44.1 26% |
77.55 ± 14.26 0% |
85.98 ± 25.69 24% | < 0.001 |
Week 8 |
94.98 ± 37.93 13% |
97.05 ± 39.27 29% | 87.73 ± 30.95 |
99.93 ± 42.08 11% | 0.312 |
Week 12 |
99.46 ± 41.84 9% |
102.86 ± 46.37 25% | 90.16 ± 30.62 |
105.31 ± 45.67 6% | 0.17 |